Description
AHU-377 is a prodrug that is metabolized to the active form, LBQ657; this compound inhibits neprilysin, preventing degradation of atrial natriuretic peptide (ANP) and brain-derived natriuretic peptide (BNP). AHU-377 displays vasodilatory and antihypertensive properties. AHU-377 is currently in clinical trials as a potential treatment for several cardiovascular indications such as congestive heart failure (CHF) and hypertension.
